相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serotonin Reuptake Inhibitor Antidepressants and Abnormal Bleeding: A Review for Clinicians and a Reconsideration of Mechanisms
Chittaranjan Andrade et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Laurent Bonello et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis
K. Przyklenk et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
J. M. Siller-Matula et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation
Yu-Lun Tseng et al.
THROMBOSIS RESEARCH (2010)
Clopidogrel in acute coronary syndrome: implications of recent study findings
Daniel Duerschmied et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2010)
Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake
Irene Lopez-Vilchez et al.
CARDIOVASCULAR RESEARCH (2009)
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Wiktor Kuliczkowski et al.
EUROPEAN HEART JOURNAL (2009)
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Lars Wallentin
EUROPEAN HEART JOURNAL (2009)
APD791, 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a Novel 5-Hydroxytryptamine 2A Receptor Antagonist: Pharmacological Profile, Pharmacokinetics, Platelet Activity and Vascular Biology
John W. Adams et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
Dirk Sibbing et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Serotonin stimulates platelet receptor shedding by tumor necrosis factor-alpha-converting enzyme (ADAM17)
D. Duerschmied et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Light Transmission Aggregometry and ATP Release for the Diagnostic Assessment of Platelet Function
Marco Cattaneo
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2009)
Sarpogrelate-Aspirin Comparative Clinical study for Efficacy and Safety in Secondary prevention of cerebral infarction (S-ACCESS) - A randomized, double-blind, aspirin-controlled trial
Yukito Shinohara et al.
STROKE (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Mechanisms of disease:: Platelet activation and atherothrombosis
Giovanni Davi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y12 receptor antagonist, compared with clopidogral in patients with acute coronary syndrome
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease
Nobuaki Kokubu et al.
CIRCULATION JOURNAL (2006)
Inhibition of 5-hydroxytryptamine(2A) receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery
K Nishihira et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: Implications for atypical antipsychotics
M Gilles et al.
PSYCHOSOMATIC MEDICINE (2005)
Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease
E Horibe et al.
CIRCULATION JOURNAL (2004)
Serotonylation of small GTPases is a signal transduction pathway that triggers platelet α-granule release
DJ Walther et al.
CELL (2003)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Sarpogrelate treatment reduces restenosis after coronary stenting
M Fujita et al.
AMERICAN HEART JOURNAL (2003)
The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts
Y Shimizu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface
GL Dale et al.
NATURE (2002)
Purification, cloning, expression, and mechanism of action of a novel platelet aggregation inhibitor from the salivary gland of the blood-sucking bug, Rhodnius prolixus
IMB Francischetti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
